Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Assessment of Safety, Tolerability, and Efficacy of LY3372689 in Early Symptomatic Alzheimer's Disease
2021-000170-29Phase 2Active
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing LY3372689 with Placebo (2 arms). Started Sep 2021; status: active.
02
Drugs
ceperognastat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2021-000170-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000170-29.